Nxera Pharma , Ltd. Profit Margin

Nxera Pharma , Ltd. (SOLTF) currently reports a profit margin of -23.31% as of June 2026. That compares with -10.48% in the prior-year period — down 122.3% year over year. That is below the Healthcare sector average of 9.71%. Use the charts on this page to explore Nxera Pharma , Ltd.'s profit margin history and peer comparisons.

Nxera Pharma , Ltd.'s profit margin decreased from -10.48% to -23.31% — a 122.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nxera Pharma , Ltd.'s profit margin of -23.31% is lower than the Healthcare sector average of 9.71%. That is roughly 340.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Nxera Pharma , Ltd.'s current -23.31% should be judged against Healthcare norms (sector average: 9.71%) and against SOLTF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -23.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.71%. From there, open related valuation or income-statement pages for Nxera Pharma , Ltd., and consider following SOLTF for alerts when major investors trade the stock.